ESSA Pharma (EPIX) Stock Price, News & Analysis

Company Overview

ESSA Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies that target KCNQ potassium ion channels, which play a critical role in the regulation of neuronal excitability. The company’s research focuses on rare neurological and neurodevelopmental disorders driven by dysfunction in these channels. By leveraging proprietary small-molecule chemistry, ESSA Pharma aims to address underlying disease mechanisms rather than merely treating symptoms.

The company’s lead candidate, EPI-589, is an orally delivered small molecule designed to upregulate KCNQ channel activity. EPI-589 is currently being evaluated in clinical trials for Temple-Baraitser syndrome and KCNQ2 developmental and epileptic encephalopathy, two ultra-rare genetic conditions characterized by severe seizures, developmental delays and motor impairments. In addition to EPI-589, ESSA Pharma maintains a preclinical pipeline of novel modulators intended to expand its portfolio into other disorders linked to KCNQ dysfunction.

Founded in Canada and headquartered in Vancouver, ESSA Pharma conducts its research and clinical programs across North America and Europe. The company collaborates with leading academic institutions and patient advocacy groups to design trials that address the unique challenges of rare disease studies, including small patient populations and high unmet medical need.

ESSA Pharma is led by a management team with deep expertise in neuroscience drug development, translational research and regulatory strategy. The company is publicly traded on the Nasdaq Stock Market under the ticker symbol EPIX and is committed to advancing precision therapies that have the potential to transform outcomes for patients living with rare neurological disorders.

Key Stats

• Today's Range: $0.20 to $0.20
• 50-Day Range: $0.19 to $0.24
• 52-Week Range: $0.18 to $1.94
• Volume: N/A
• Average Volume: 3.75 million shs
• Market Capitalization: $9.52 million
• P/E Ratio: N/A
• Dividend Yield: 839.96%
• Price Target: N/A
• Consensus Rating: Sell

ESSA Pharma Stock Analysis - MarketRank™

ESSA Pharma scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

ESSA Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ESSA Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ESSA Pharma are expected to grow in the coming year, from ($0.42) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ESSA Pharma is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ESSA Pharma is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ESSA Pharma has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for EPIX.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

ESSA Pharma is a leading dividend payer. It pays a dividend yield of 840.47%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

ESSA Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for EPIX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ESSA Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.50% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 5/08/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPIX
• CIK: 1633932
• Web: www.essapharma.com
• Phone: 778-331-0962
• Fax: 604-738-4080
• Employees: 50
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.71%
• Return on Assets: -21.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 69.06
• Quick Ratio: 69.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 47,308,000
• Free Float: 39,975,000
• Market Cap: $9.52 million
• Optionable: Optionable
• Beta: 1.57